Role of immune mediators in predicting hospitalization of SARS-CoV-2 positive patients.
Adult
Area Under Curve
Biomarkers
C-Reactive Protein
/ analysis
COVID-19
/ immunology
Chemokines
/ blood
Cytokines
/ blood
Female
Ferritins
/ blood
Fibrin Fibrinogen Degradation Products
/ analysis
Hospital Mortality
Hospitalization
Humans
Interleukin-6
/ blood
Length of Stay
/ statistics & numerical data
Male
Middle Aged
Prognosis
ROC Curve
Receptors, Chemokine
/ physiology
Receptors, Cytokine
/ physiology
Respiration, Artificial
/ statistics & numerical data
SARS-CoV-2
Severity of Illness Index
Treatment Outcome
COVID-19
Hospitalization
IL-6
Immune mediator
Multiplex assay
SARS-CoV-2
Journal
Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
22
07
2021
revised:
02
12
2021
accepted:
14
12
2021
pubmed:
7
1
2022
medline:
27
1
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
Several immune mediators (IM) including cytokines, chemokines, and their receptors have been suggested to play a role in COVID-19 pathophysiology and severity. To determine if early IM profiles are predictive of clinical outcome and which of the IMs tested possess the most clinical utility. A custom bead-based multiplex assay was used to measure IM concentrations in a cohort of SARS-CoV-2 PCR positive patients (n = 326) with varying disease severities as determined by hospitalization status, length of hospital stay, and survival. Patient groups were compared, and clinical utility was assessed. Correlation plots were constructed to determine if significant relationships exist between the IMs in the setting of COVID-19. In PCR positive SARS-CoV-2 patients, IL-6 was the best predictor of the need for hospitalization and length of stay. Additionally, MCP-1 and sIL-2Rα were moderate predictors of the need for hospitalization. Hospitalized PCR positive SARS-CoV-2 patients displayed a notable correlation between sIL-2Rα and IL-18 (Spearman's ρ = 0.48, P=<0.0001). IM profiles between non-hospitalized and hospitalized patients were distinct. IL-6 was the best predictor of COVID-19 severity among all the IMs tested.
Sections du résumé
BACKGROUND
Several immune mediators (IM) including cytokines, chemokines, and their receptors have been suggested to play a role in COVID-19 pathophysiology and severity.
AIM
To determine if early IM profiles are predictive of clinical outcome and which of the IMs tested possess the most clinical utility.
METHODS
A custom bead-based multiplex assay was used to measure IM concentrations in a cohort of SARS-CoV-2 PCR positive patients (n = 326) with varying disease severities as determined by hospitalization status, length of hospital stay, and survival. Patient groups were compared, and clinical utility was assessed. Correlation plots were constructed to determine if significant relationships exist between the IMs in the setting of COVID-19.
RESULTS
In PCR positive SARS-CoV-2 patients, IL-6 was the best predictor of the need for hospitalization and length of stay. Additionally, MCP-1 and sIL-2Rα were moderate predictors of the need for hospitalization. Hospitalized PCR positive SARS-CoV-2 patients displayed a notable correlation between sIL-2Rα and IL-18 (Spearman's ρ = 0.48, P=<0.0001).
CONCLUSIONS
IM profiles between non-hospitalized and hospitalized patients were distinct. IL-6 was the best predictor of COVID-19 severity among all the IMs tested.
Identifiants
pubmed: 34991059
pii: S1043-4666(21)00379-3
doi: 10.1016/j.cyto.2021.155790
pmc: PMC8709828
pii:
doi:
Substances chimiques
Biomarkers
0
Chemokines
0
Cytokines
0
Fibrin Fibrinogen Degradation Products
0
IL6 protein, human
0
Interleukin-6
0
Receptors, Chemokine
0
Receptors, Cytokine
0
fibrin fragment D
0
C-Reactive Protein
9007-41-4
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155790Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Ann Intensive Care. 2021 Jan 13;11(1):9
pubmed: 33439360
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Sci Rep. 2020 Dec 10;10(1):21697
pubmed: 33303843
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Curr Pharmacol Rep. 2020;6(3):53-55
pubmed: 32395419
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell Mol Immunol. 2020 Aug;17(8):878-880
pubmed: 32587367
Int J Neonatal Screen. 2021 Apr 23;7(2):
pubmed: 33922835
BMC Infect Dis. 2021 Mar 29;21(1):308
pubmed: 33781216
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32706339
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
Annu Rev Immunol. 2001;19:423-74
pubmed: 11244043
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Sci Immunol. 2021 Mar 10;6(57):
pubmed: 33692097
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Front Oncol. 2020 Jan 31;9:1529
pubmed: 32076597